Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

2010/09/21 by SHARP Collaborative Group · 30 citations
Medicine · #Lipoproteins and Cardiovascular Health #Chronic Kidney Disease and Diabetes #Blood Pressure and Hypertension Studies

paper · doi:10.1016/j.ahj.2010.08.012

Cited by

• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
• Management of residual risk after statin therapy
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
• Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
• Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. [europepmc]
• Rosuvastatin in diabetic hemodialysis patients. [europepmc]
• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. [europepmc]
• Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. [europepmc]
• Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. [europepmc]
• Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. [europepmc]
• Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. [europepmc]
• Effects of lowering LDL cholesterol on progression of kidney disease. [europepmc]
• Lipid mediators in diabetic nephropathy. [europepmc]
• Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. [europepmc]
• What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? [europepmc]
• PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. [europepmc]
• A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. [europepmc]
• Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. [europepmc]
• Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. [europepmc]
• Associations of statin use with glycaemic traits and incident type 2 diabetes. [europepmc]
• Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. [europepmc]
• Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. [europepmc]
• Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. [europepmc]
• Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. [europepmc]
• Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study. [europepmc]
• Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). [europepmc]
• Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. [europepmc]
• 2023 Chinese guideline for lipid management. [europepmc]
• Novel Insights into Diabetic Kidney Disease. [europepmc]